

Product datasheet for **TR320514**

BRD2 Human shRNA Plasmid Kit (Locus ID 6046)

Product data:

Product Type:	shRNA Plasmids
Product Name:	BRD2 Human shRNA Plasmid Kit (Locus ID 6046)
Locus ID:	6046
Synonyms:	BRD2-IT1; D6S113E; FSH; FSRG1; NAT; O27.1.1; RING3; RNF3
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	BRD2 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 6046). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	NM_001113182 , NM_001199455 , NM_001199456 , NM_001291986 , NM_005104 , NR_037625 , NM_005104.1 , NM_005104.2 , NM_005104.3 , NM_001113182.1 , NM_001113182.2 , NM_001199456.1 , NM_001199455.1 , NM_001291986.1 , BC000477 , BC001885 , BC007715 , BC063840 , NM_001291986.2 , NM_001113182.3
UniProt ID:	P25440
Summary:	This gene encodes a transcriptional regulator that belongs to the BET (bromodomains and extra terminal domain) family of proteins. This protein associates with transcription complexes and with acetylated chromatin during mitosis, and it selectively binds to the acetylated lysine-12 residue of histone H4 via its two bromodomains. The gene maps to the major histocompatibility complex (MHC) class II region on chromosome 6p21.3, but sequence comparison suggests that the protein is not involved in the immune response. This gene has been implicated in juvenile myoclonic epilepsy, a common form of epilepsy that becomes apparent in adolescence. Multiple alternatively spliced variants have been described for this gene. [provided by RefSeq, Dec 2010]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com . If you need a special design or shRNA sequence, please utilize our custom shRNA service .



[View online »](#)

**Performance
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).